InvisiShield Technologies said that it will speed up its H5N1 / Pan-influenza intranasal antibodies development program in response to recent outbreaks of H5N1 avian flu in mammals. The company says that it can move quickly into clinical development because it previously held successful pre-IND meetings with the FDA regarding its IS101 intranasal antibody fusion protein against SARS-CoV-2.
According to InvisiShield, its intranasal antibodies are capable of stopping viral shedding from people already infected as well as preventing infection in the first place. In addition, the company notes that the antibodies offer protection to elderly and immunocompromised individuals and are highly scalable. In addition to IS101 and the pan-influenza antibody program, InvisiShield’s pipeline includes a nasal antibody against RSV.
InvisiShield Technologies President and Chief Scientific Officer Warner C. Greene commented, “The recent spread of H5N1 avian flu more broadly in mammals is a wake-up call to the global health community. If H5N1 acquires mutations that allow for its efficient spread among humans while retaining its pathogenicity, it could trigger a devastating public health crisis. By accelerating our H5N1/Pan-influenza program, we aim to deliver groundbreaking solutions that protect against potential deadly pandemic outbreaks and redefine how we safeguard public health beyond traditional vaccines and systemic interventions.”
CEO Michael Smith added, “Combatting the challenges of H5N1 requires not only innovative, breakthrough science but also a sense of urgency. Our H5N1/Pan-influenza candidates, engineered with proprietary mucoadhesive domain technology, robustly prevent infection and significantly lower infection rates by effectively breaking the chain of transmission across all influenza A&B strains, including H5N1. Advancing to clinical trials will confirm the potential of this paradigm-shifting approach and reinforce our commitment to pioneering innovative solutions in respiratory viral protection.”
Read the InvisiShield Technology press release
